

Eurofins Discovery Enhances its Fragment and PROTAC Drug Discovery Capabilities



St. Charles, MO, September 29, 2021 /PRNewswire/ -- Eurofins Discovery, the leading provider of products and services to the drug discovery industry and a Eurofins Scientific (EUFI.PA) company, announces a collaboration with Liverpool ChiroChem Ltd (LCC) to provide enhanced chemical expertise by accessing LCC's fragment library and PROTAC linker molecules to augment their integrated drug discovery platform, DiscoveryOne™. Eurofins' DiscoveryOne™ offers comprehensive services from Hit Identification to Lead Optimization across a wide range of target classes and therapeutic areas. The collaboration with LCC enables Eurofins Discovery to expand its capabilities for virtual and fragment screening in addition to strengthening its growing PROTAC platform.

Eurofins Discovery and LCC will combine their proprietary compound collections and utilize Eurofins Discovery's innovative drug discovery solutions to provide a high-quality fragment and virtual screening. Breakthrough biotech and pharmaceutical companies worldwide will significantly benefit from this strategic collaboration between Eurofins Discovery and LCC through access to these enhanced libraries which will increase the likelihood of identifying tractable starting points with the potential for rapid optimization in a fully integrated setting.

As a leading global innovation-driven and customer-focused provider, Eurofins Discovery values the culture of collaboration and the unrelenting pursuit of scientific excellence which will be strengthened through the collaboration with LCC.

For further information

www.eurofinsdiscoveryservices.com

Media Contact

Aida Yodites, Director Marketing Communications
aidayodites@eurofinsus.com

About Eurofins Discovery

Eurofins Discovery has supported Drug Discovery research for over 40 years. Eurofins is recognized as the industry leader for providing drug discovery researchers the largest and most diverse portfolio of standard and custom *in vitro* safety & pharmacology assays and panels for drug screening and profiling. In addition to *in vitro* safety pharmacology strengths, we also offer a broad portfolio of over 3,500 drug discovery services and 1,800 products. These include *in vitro* assays, cell-based phenotypic assays, safety pharmacology and efficacy, ADME toxicology, medicinal chemistry design, synthetic chemistry, and custom proteins and assay development capabilities. We support a variety of drug discovery targets such as GPCRs, Kinases, Ion Channels, Nuclear Hormone Receptors and other proteins & enzymes. The Eurofins Discovery capabilities, expertise, knowledge and skill sets enable the company to provide clients the benefit of being able to work with a single outsourcing provider (CRO) for all their drug discovery programs.

Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, and pharmaceutical product testing. It is also one of the market leaders in testing and laboratory services for genomics, discovery pharmacology,

forensics, advanced material sciences and has a rapidly developing presence in highly specialized and molecular clinical diagnostic testing.

With over 55,000 staff across a network of more than 900 laboratories in over 50 countries, Eurofins' companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

About Liverpool ChiroChem (LCC)

LCC is a chemical technology innovator, on a mission to accelerate NCE discovery and development through improved access to 3D chemical space. Its suite of in-house synthetic methodologies and production capabilities have already enabled the production of >3,000 novel, stereodefined, multifunctionalized (N)-heterocycles. LCC's fragments, scaffolds, linkers and lead-like virtual library support Hit Identification and its novel building block collection supports efficient Lead Optimization.

LCC was founded in 2014 and has operations in the UK and China, serving a global customer base within the life science sector.

###